MIT's Nanoparticles Repeat a Fifteen-Year Failure

MIT announced nanoparticles that deliver messenger RNA directly into tumor cells, reprogramming the immune system to recognize and attack cancer — a breakthrough that journalists celebrated, though the field tried this exact approach fifteen years ago and abandoned it completely.

In 2008, CalTech and Leukosite Therapeutics published elegant work on nanoparticle vectors designed to home in on tumors like guided missiles. By 2012, clinical trials began. Within three years the work dissolved into silence — not from danger, but because the nanoparticles couldn't reliably cross the blood-brain barrier, couldn't survive immune recognition of foreign objects, and couldn't overcome "immunological noise," the chaos of a living body that bears no resemblance to petri dishes or mouse models.

The structural trap is always the same. A mechanism works in isolation, then variables multiply in a human body. The researchers who designed the system believed deeply in their own elegance. That belief itself became an obstacle. It required finding what broke rather than accepting the mechanism was incomplete.

What's different this time is testable. Either MIT's team solved the specific barrier. Show the pathway, the survival rate through circulation, the clinical efficacy numbers. Or they've simply reset the clock on the same unsolved problem with better marketing and a new acronym. Watch how they talk about uncertainty now. Anyone defending an elegant mechanism too early speaks with absolute confidence, while anyone who's actually solved an engineering problem speaks about the specific thing that still might fail.

The difference reveals itself in how certainty is claimed.